Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
RESEARCH TOOLSreports
Holding TSE:CRDL?
Track your performance easily
CRDL Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.02 - C$4.26
Previous CloseC$2.78
Volume103.41K
Average Volume (3M)119.68K
Market Cap
C$202.66M
Enterprise ValueC$167.90M
Total Cash (Recent Filing)C$34.93M
Total Debt (Recent Filing)C$174.34K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 12, 2024EPS Estimate
-C$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding69,881,720
10 Day Avg. Volume72,211
30 Day Avg. Volume119,681
Standard Deviation0.22
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$12.49Price Target Upside349.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cardiol Therapeutics News
PremiumCompany Announcements
Cardiol Therapeutics Expands Trials for Heart Treatment
PremiumCompany Announcements
Cardiol Therapeutics Raises $15.5 Million in Offering
PremiumCompany Announcements
Cardiol Therapeutics Secures $13.5M in Public Offering
PremiumCompany Announcements
Cardiol Therapeutics Sets Common Share Offering Price
PremiumCompany Announcements
Cardiol Therapeutics Announces Public Share Offering
PremiumCompany Announcements
Cardiol Therapeutics’ Landmark Enrollment for Heart Drug Trial
PremiumCompany Announcements
Cardiol Therapeutics Advances Heart Disease TreatmentOptions Prices
Currently, No data available
---
Ownership Overview
4.40% Insiders
0.08% Mutual Funds
0.84% Other Institutional Investors
92.69% Public Companies and
Individual Investors
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.02 and its highest was C$4.26 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Currently, no data Available
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2024. The company reported -C$0.1 earnings per share for the quarter, beating the consensus estimate of -C$0.141 by C$0.041.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -C$0.13.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 69,881,720 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.1 in its last earnings report, beating expectations of -C$0.141. Following the earnings report the stock price went up 3.61%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
---
Cardiol Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$12.49 (349.16% Upside)
C$12.49 (349.16% Upside)
Blogger Sentiment
Bullish
TSE:CRDL Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
140.33%
12-Months-Change
Fundamentals
Return on Equity
-106.90%
Trailing 12-Months
Asset Growth
-46.06%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics, Inc. is a biotechnology company, which engages in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for inflammatory diseases. Its products pipelines include heart failure products, glioblastoma multiforme and pharmaceutical cannabidol. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
---
CRDL Stock 12 Month Forecast
Average Price Target
C$12.49
▲(349.16% Upside)
Technical Analysis
Cardiol Therapeutics
―
Bioxcel Therapeutics
―
Cyclerion Therapeutics
―
Immunic
―
Mind Medicine
―
Best Analysts Covering CRDL
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+35.91%
reiterated a buy rating 19 days ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +35.91% per trade.
---